[Cotrimoxazole induced dermatitis and curative treatment of AIDS pneumocystosis] NLM AIDSLINE Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


[Cotrimoxazole induced dermatitis and curative treatment of AIDS pneumocystosis]

Rev Mal Respir. 1996;13(2):101-6. Unique Identifier : AIDSLINE MED/96272057
Caumes E; Service des Maladies Infectieuses et Tropicales, Hopital; Pitie-Salpetriere, Paris.

Abstract: Adverse cutaneous reactions frequently occur during the treatment of AIDS associated pneumocystosis by trimethoprime-sulfamethoxazole. The most common form is a maculous rash. Treating throughout the duration of hypersensitivity may lead to potentially lethal Stevens-Johnson and Lyell syndromes. Slow acetylator phenotype, a glutathion deficiency and a history of adverse cutaneous reactions have been identified as risk factors of cutaneous reactions. An adjuvant corticosteroid therapy decreases the frequency of adverse cutaneous reactions during the treatment of hypoxaemic pneumocystosis by trimethoprim-sulfamethoxazole.
Keywords: Anti-Infective Agents/*ADVERSE EFFECTS AIDS-Related Opportunistic Infections/*DRUG THERAPY Drug Eruptions/*ETIOLOGY/PHYSIOPATHOLOGY English Abstract Epidermal Necrolysis, Toxic/ETIOLOGY Human Incidence Pneumonia, Pneumocystis carinii/*DRUG THERAPY Risk Factors Stevens-Johnson Syndrome/CHEMICALLY INDUCED Treatment Outcome Trimethoprim-Sulfamethoxazole Combination/*ADVERSE EFFECTS JOURNAL ARTICLE REVIEW REVIEW, TUTORIALKWDanti-infectiveagents/KWDadverseeffectsaids-relatedopportunisticinfections/KWDdrugtherapydrugeruptions/KWDetiology/physiopathologyenglishabstractepidermalnecrolysis,toxic/etiologyhumanincidencepneumonia,pneumocystiscarinii/KWDdrugtherapyriskfactorsstevens-johnsonsyndrome/chemicallyinducedtreatmentoutcometrimethoprim-sulfamethoxazolecombination/KWDadverseeffectsjournalarticlereviewreview,tutorial
961130
M96B1389

Copyright © 1996 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .